A case of polymyositis in a chronic hepatitis C patient treated with peg-interferon-alpha 2b and ribavirin therapy

Clinical Journal of Gastroenterology

Volumn 2, Issue 5, 2009, Pages 346-350

  Okuma, Yusuke ^a   Kimura, Kiminori ^a   Saeki, Shunichi ^a   Hishima, Tsunekazu ^a   Hayashi, Seishu ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

Chronic hepatitis C; Peg interferon alpha and ribavirin therapy; Polymyositis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; LACTATE DEHYDROGENASE; PEGINTERFERON ALPHA2B; PREDNISOLONE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; URSODEOXYCHOLIC ACID; VIRUS RNA;

ABSENCE OF SIDE EFFECTS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; COMBINATION CHEMOTHERAPY; CORTICOSTEROID THERAPY; CREATINE KINASE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LACTATE DEHYDROGENASE BLOOD LEVEL; MUSCLE BIOPSY; POLYMYOSITIS; PRIORITY JOURNAL; REMISSION; SIDE EFFECT;

EID: 70350761830     PISSN: 18657257     EISSN: 18657265     Source Type: Journal    
DOI: 10.1007/s12328-009-0101-0     Document Type: Article

References (12)

1. A John S El Emadi S Al Kaabi, et al. 2007 Polymyositis during pegylated alpha-interferon ribavirin therapy for chronic hepatitis Indian J Gastroenterol 26 147 148 17704594
2. CM Perry B Jarvis 2001 Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C Drugs 61 2263 2288 10.2165/00003495-200161150-00013 1:CAS:528:DC%2BD38XnsVWmtA%3D%3D 11772139
3. GM Keating MP Curran 2003 Peginterferon-alpha-2a (40 kD) plus ribavirin: a review of its use in the management of chronic hepatitis C Drugs 63 701 730 10.2165/00003495-200363070-00008 1:CAS:528:DC%2BD3sXjsVWgt7c%3D 12656650
4. MP Manns JG McHutchison SC Gordon, et al. 2001 Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial Lancet 358 958 965 10.1016/S0140-6736(01)06102-5 1:CAS:528:DC%2BD3MXntF2qtb8%3D 11583749
5. M Simin J Brok D Stimac, et al. 2007 Cochrane systematic review: pegylated interferon plus ribavirin vs interferon plus ribavirin for chronic hepatitis C Aliment Pharmacol Ther 25 1153 1162 1:CAS:528:DC%2BD2sXmtlert78%3D 17451561
6. G Venezia A Bicata V Di Marco, et al. 2005 Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b Dig Liver Dis 37 882 885 10.1016/j.dld.2005.06.010 1:STN:280:DC%2BD2MrmsFCnug%3D%3D 16169301
7. H Iguchi M Kishi T Fujioka, et al. 1996 Polymyositis after interferon beta treatment of chronic hepatitis type C Rinsho Shinkeigaku 36 22 24 1:STN:280:DyaK283ptV2hsw%3D%3D 8689784
8. M Matsuya T Abe M Tosaka, et al. 1994 The first case of polymyositis associated with interferon therapy Intern Med 33 806 808 10.2169/ internalmedicine.33.806 1:STN:280:DyaK2M3jsFWgtQ%3D%3D 7718967
9. H Arai M Tanaka K Ohta, et al. 1995 Symptomatic myopathy associated with interferon therapy for chronic hepatitis C Lancet 345 582 10.1016/S0140-6736(95) 90490-5 1:STN:280:DyaK2M3psFCntQ%3D%3D 7677847
10. Y Nagane K Utsugisawa H Kizawa, et al. 2005 Hypothyroid myopathy caused by interferon-alpha therapy for chronic hepatitis C Rinsho Shinkeigaku 45 441 444 16022470
11. Kouno H, Aimitsu S, Ikemoto Y, et al. Cardiovascular complications of interferon therapy in chronic hepatitis C. Nippon Rinsho. 1994;52:1914-8.
12. SA Greenberg 2007 A gene expression approach to study perturbed pathways in myositis Curr Opin Rheumatol 19 536 541 10.1097/BOR.0b013e3282efe261 17917532